• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Luna Announces Updates on Operating Metrics and Intent to Deregister Stock

    1/27/25 10:24:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $LUNA alert in real time by email

    Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announces an update on select operating metrics. The Company is also communicating its intent to voluntarily accelerate its delisting from Nasdaq and ultimately deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including suspending its reporting obligations under Section 15(d) of the Exchange Act. The accelerated delisting and deregistration process will not adversely affect Luna's ongoing operations or the listing of the Company's common stock on the OTC Experts Market.

    "Luna started 2024 with a series of challenges which generated headwinds in the first half of the year. Despite these challenges, our team demonstrated resilience and commitment to customers, suppliers and innovation, with results materializing in the second half of 2024," said the Company's President, Chief Executive Officer and board member, Kevin Ilcisin.

    Mr. Ilcisin added, "Having strengthened our management team and deepened our customer and supplier relationships, the company experienced improved performance in both bookings and revenue during the second half of 2024. These results stand as a testament to our dedicated employees and channel partners. We are grateful for the ongoing trust and partnership of our customers and suppliers through this period."

    Mr. Ilcisin continued, "While the Luna team has been working diligently to complete its previously disclosed delinquent filings, we are unable to file them within Nasdaq's prescribed timeline. As a result, Nasdaq has notified us of its intent to delist our common stock. Given the pending delisting, we have made a strategic decision to accelerate the delisting and terminate and suspend the Company's reporting obligations under the Exchange Act. The Company believes these decisions provide the best path forward, given the expected cost savings and our current inability to realize the traditional benefits of public company status. Moreover, we believe this move will redirect resources from regulatory compliance to business operations, including delivering differentiated products and solutions to our valued customers. This focus aims to further strengthen our balance sheet and maintain a profitable growth trajectory going forward. As we execute these changes, the Company continues to explore strategic alternatives having engaged Evercore as the Company's financial advisor."

    Business Update

    Will Denman, SVP and GM of the Optical Communications Test business, highlighted how his organization "secured numerous exciting Tier 1 customer wins in the rapidly expanding data center, artificial intelligence, and quantum spaces. New product developments are enabling wins with several of the world's leading Fusion Energy projects that are supporting the energy demand being created by AI data center investments."

    Thomas Oldemeyer, SVP and Managing Director of EMEA, reported how key customers in the Oil and Gas and Power Utilities market continued to rely on Luna products and teams for critical infrastructure projects resulting in several multi-million dollar wins. "We are especially proud of the strong response of our customer base to the release of our latest Atlas Interrogation Unit comprising state-of-the-art Distributed Acoustic Sensing Technology." Throughout the year, the team also successfully accomplished the first phases of its integration of Silixa, which was acquired in December of 2023.

    According to preliminary estimates which are subject to change, the Company expects the following financial results for its fiscal year ended December 31, 2024:

    • Bookings are expected to be between $125 million and $130 million, with bookings for the second half of fiscal 2024 representing approximately 40% growth relative to the first half of the year. Backlog as of December 31, 2024 is expected to exceed $40 million.
    • Revenue is expected to be between $110 million and $115 million. Revenue for the second half of 2024 is expected to be approximately 30% higher than in the first half of 2024.

    SEC Deregistration Process

    As noted above, the Company has determined it is in the best interest of the Company and its stockholders to eliminate the administrative burden and cost associated with remaining as a Securities and Exchange Commission (the "SEC") registrant. The Company today notified Nasdaq of its intent to accelerate the delisting of its common stock from Nasdaq. The Company currently anticipates that it will file with the SEC a Form 25 relating to the delisting and deregistration of its common stock on or about February 6, 2025.

    Preliminary Unaudited Financial Information

    This press release contains preliminary estimates of selected unaudited financial and other information for the Company's fiscal year ended December 31, 2024. Our full audited condensed consolidated financial statements as of and for the year ended December 31, 2024 are not yet available. The information contained herein reflects our preliminary estimates based on currently available information and is subject to change. We have provided ranges, rather than specific amounts, for the preliminary estimates of the financial information described herein primarily because our financial closing procedures for the year ended December 31, 2024 are not yet complete and, as a result, our final results upon completion of our closing procedures may vary from the preliminary estimates.

    Forward-Looking Statements

    The statements in this release that are not historical facts constitute "forward-looking statements" made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include, but are not limited to, expected financial results for 2024 and statements made in the President and Chief Executive Officer's quotes regarding the Company's expected and future financial and operational results, and well as the Company's plans to delist the Company's common stock from Nasdaq and deregister the Company's common stock from the SEC. Management cautions the reader that these forward-looking statements are only predictions and are subject to a number of both known and unknown risks and uncertainties, and actual results, performance, and/or achievements of the Company may differ materially from the future results, performance, and/or achievements expressed or implied by these forward-looking statements because of a number of factors. These factors include, without limitation, risks and uncertainties set forth in the sections entitled "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, as well as in subsequent filings with the Securities and Exchange Commission ("SEC"). Such filings are available on the SEC's website at www.sec.gov and on Luna's website at www.lunainc.com. The statements made in this release are based on information available to Luna as of the date of this release and Luna undertakes no obligation to update any of the forward-looking statements after the date of this release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250127974484/en/

    Investor Contact:

    Allison Woody

    Luna Innovations Incorporated

    Phone: 540.769.8465

    Email: woodya@lunainc.com

    Get the next $LUNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LUNA

    DatePrice TargetRatingAnalyst
    7/28/2023$12.50Buy
    Stifel
    5/22/2023$10.00Buy
    Needham
    3/15/2023$8.00Outperform → Market Perform
    Northland Capital
    5/23/2022$8.00Market Perform → Outperform
    Northland Capital
    More analyst ratings

    $LUNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Luna Innovations with a new price target

    Stifel initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $12.50

    7/28/23 7:35:40 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Needham initiated coverage on Luna Innovations with a new price target

    Needham initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $10.00

    5/22/23 7:57:49 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations downgraded by Northland Capital with a new price target

    Northland Capital downgraded Luna Innovations from Outperform to Market Perform and set a new price target of $8.00

    3/15/23 8:52:49 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Spiegel Gary converted options into 10,672 shares, increasing direct ownership by 15% to 81,625 units (SEC Form 4)

    4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

    1/3/25 4:44:17 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Anderson N Leigh converted options into 19,869 shares, increasing direct ownership by 122% to 36,102 units (SEC Form 4)

    4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

    1/3/25 4:43:48 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Coe Pamela L converted options into 13,372 units of Common Stock (SEC Form 4)

    4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

    12/26/24 5:52:51 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    SEC Filings

    View All

    Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

    1/27/25 10:26:44 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated

    SCHEDULE 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

    1/14/25 1:56:29 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

    1/6/25 8:30:40 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Luna Innovations Reports Q3 2025 Results Including Continued Bookings Growth and Margin Expansion

    Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber-optic technology, today announced preliminary unaudited financial results for the third quarter ended September 30, 2025. The Company reported continued growth in bookings, revenue, and positive cash generation. "Our third quarter performance reflects disciplined execution and sustained attractiveness of our core markets," said Kevin Ilcisin, President and Chief Executive Officer of Luna. "Both our Optical Communications and Sensing businesses delivered growth while we continued to improve margins and strengthen liquidity." Financial Highlights for the Third Quarter Ended September 30, 20

    11/4/25 8:00:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Announces Strong Start to 2025 with Substantial Bookings Growth

    Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber optic-based technology, today announced select preliminary operating and financial metrics for the first quarter ended March 31, 2025, showcasing significant year-over-year bookings growth, continued gross margin expansion, and sustained execution on cost containment initiatives. "We are pleased to report a strong start to 2025, with sharp improvements in bookings, margin performance, and working capital management," said the Company's President, Chief Executive Officer, Kevin Ilcisin. "Our continued focus on operational discipline, customer alignment, and profitable growth is positioning

    5/20/25 8:48:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations Announces Baker Tilly as New Independent Auditor

    Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

    4/2/25 8:52:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Leadership Updates

    Live Leadership Updates

    View All

    Luna Innovations Announces Baker Tilly as New Independent Auditor

    Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

    4/2/25 8:52:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Announces Resignation of Pamela Coe

    Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, Pamela Coe, a member of the Board of Directors (the "Board"), will be retiring from the Luna board effective today. Ms. Coe was elected to the Board in May 2021 for a three-year term. "We are very grateful for Pam's notable contributions and leadership throughout her time on the Board," said Barry Phelps, Chairman of the Board of the Company. "Her expertise, focus and commitment have been instrumental in guiding Luna. We wish Pam all the best in her future endeavors." About Luna Luna Innovations Incorporated (www.lunainc.com) is a leader in optic

    12/27/24 4:40:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations Announces CFO Transition: Names William Phelan as Chief Financial Officer and Chief Accounting Officer

    Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the appointment of William L. Phelan as its new Chief Financial Officer and Chief Accounting Officer, effective immediately. Mr. Phelan succeeds John Roiko, who joined Luna out of retirement in May 2024 and played a key role in establishing a resilient foundation for Luna's future growth. Following the appointment of Mr. Phelan, Mr. Roiko will shift to a consulting role to support the ongoing restatement process. "We are delighted to welcome Bill to the Luna leadership team," said Kevin Ilcisin, President and CEO of Luna. "Bill's highly relevant experience will be instrume

    10/16/24 4:30:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Financials

    Live finance-specific insights

    View All

    Luna Innovations Reports Q3 2025 Results Including Continued Bookings Growth and Margin Expansion

    Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber-optic technology, today announced preliminary unaudited financial results for the third quarter ended September 30, 2025. The Company reported continued growth in bookings, revenue, and positive cash generation. "Our third quarter performance reflects disciplined execution and sustained attractiveness of our core markets," said Kevin Ilcisin, President and Chief Executive Officer of Luna. "Both our Optical Communications and Sensing businesses delivered growth while we continued to improve margins and strengthen liquidity." Financial Highlights for the Third Quarter Ended September 30, 20

    11/4/25 8:00:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations to Delay Release of Fourth Quarter and Full Year 2023 Financial Results

    Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced it will delay the release of its fourth quarter and fiscal year 2023 financial results and the subsequent conference call. A Special Committee of the Company's Board of Directors is conducting an independent review, with the assistance of external legal and financial advisors, of certain transactions for which revenue was recognized in the second and third quarters of 2023 that did not qualify for revenue recognition under U.S. generally accepted accounting principles. The Special Committee is examining the circumstances surrounding these issues and is eva

    3/12/24 4:20:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

    Investment Proceeds Used to Fund Silixa Acquisition and Enhance Luna's Financial Flexibility to Pursue Strategic Growth Initiatives Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced a $50 million investment by White Hat Capital Partners ("White Hat"), an investment firm focused on sustainable value creation in technology companies serving mission-critical applications. Proceeds from this strategic investment were partially used to fund the acquisition of Silixa, also announced today, and related transaction costs in the aggregate amount of approximately $25 million. Remaining proceeds were used to repay the Company's o

    12/21/23 9:34:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Luna Innovations Incorporated

    SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

    11/14/24 12:32:28 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by Luna Innovations Incorporated

    SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

    11/14/24 8:39:20 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Luna Innovations Incorporated

    SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

    11/12/24 4:02:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care